

Table 4.4
Counts (Annualized Percentages) of Participants with Self-Reported Outcomes by Race/Ethnicity for SRC Super Cohort Participants¹ Who Did Not Report a Prevalent Condition at Baseline

Data as of: February 19, 2022; Events through February 19, 2022

Outcomes	Race/Ethnicity						
	American Indian/ Alaska Native	Asian or Native Hawaiian/ Other Pacific Islander ²	Hispanic/ Latina	Non-Hispanic Black/African American	Non-Hispanic White	More than one Race	Other/Not Reported
Number of participants	379	3558	787	142	111050	1119	599
Mean follow-up (months)	153.4	177.4	212.8	191.9	209.8	213.7	137.9
DVT	5 (0.11%)	42 (0.08%)	30 (0.22%)	11 (0.52%)	4554 (0.24%)	54 (0.28%)	12 (0.18%)
Pulmonary embolism ³	6 (0.13%)	16 (0.03%)	9 (0.06%)	5 (0.23%)	2876 (0.15%)	21 (0.11%)	9 (0.13%)
Angina (hospitalized) ⁴	17 (0.38%)	141 (0.28%)	70 (0.52%)	14 (0.69%)	9279 (0.50%)	132 (0.70%)	24 (0.37%)
Diabetes (treated)	66 (1.56%)	587 (1.17%)	156 (1.17%)	38 (1.78%)	17457 (0.92%)	219 (1.15%)	87 (1.33%)
Hysterectomy	13 (0.53%)	125 (0.36%)	42 (0.47%)	5 (0.46%)	6855 (0.59%)	53 (0.51%)	22 (0.53%)
Osteoarthritis ⁵	99 (3.60%)	1180 (3.11%)	302 (3.61%)	44 (3.32%)	37104 (3.21%)	399 (3.29%)	136 (3.16%)
Intestinal polyps	71 (1.58%)	761 (1.60%)	227 (1.79%)	45 (2.16%)	29351 (1.65%)	302 (1.67%)	121 (1.90%)
Lupus ⁵	10 (0.22%)	39 (0.08%)	13 (0.10%)	2 (0.09%)	1840 (0.10%)	31 (0.17%)	11 (0.17%)
Hypertension treated w/pills	121 (3.78%)	1185 (3.17%)	345 (3.25%)	56 (4.51%)	44340 (3.04%)	455 (3.25%)	173 (3.57%)
COPD ⁶	17 (0.53%)	109 (0.33%)	61 (0.87%)	10 (0.80%)	8161 (0.84%)	102 (1.05%)	13 (0.26%)
Macular degeneration ⁷	27 (0.58%)	277 (0.61%)	137 (1.36%)	9 (0.52%)	18904 (1.34%)	182 (1.28%)	44 (0.63%)
Dementia ⁷	33 (0.71%)	309 (0.68%)	129 (1.28%)	18 (1.03%)	16223 (1.15%)	182 (1.29%)	45 (0.65%)
Parkinson's disease ⁷	2 (0.04%)	48 (0.11%)	18 (0.18%)	1 (0.06%)	2348 (0.17%)	32 (0.23%)	6 (0.09%)

¹ The SRC Super Cohort includes all Non-Hispanic White, American Indian/Alaskan Native, Asian/Pacific Islander, and Unknown Race/Ethnicity participants (identified from race/ethnicity collected on Form 2 at baseline) from the Dietary Modification Trial (not also in the Hormone Trial) and the Observational Study. However, race/ethnicity is presented using the imputed Form 41 data and following the WHI Race/Ethnicity Task Force guidelines.

² Native Hawaiian/Other Pacific Islander SRC Super Cohort participants (n=79) are combined with Asian SRC Super Cohort participants for reporting purposes due to small numbers.

³ During the main WHI Study and the WHI Extension Study 2005-2010, pulmonary embolism includes only inpatient self-reports. During WHI Extension Study 2010-2025, pulmonary embolism includes both inpatient and outpatient self-reports.

⁴ During WHI Extension Study 2005-2010, the outcome was angina with hospitalization for a heart condition that may or may not have been related to the angina.

⁵ These outcomes have not been self-reported on all versions of Form 33 during WHI follow-up. The annualized percentages are corrected for the different amounts of follow-up.

⁶ Data only collected during the WHI Extension Study 2010-2025.

⁷ Data only collected during the WHI Extension Studies 2005-2025.